cetiplimab

Cetiplimab appears to be a non-existent or hallucinated drug name, likely representing a misspelling or erroneous transliteration of **thiotepa** (often referred to as **cetipae** or **saitipai** in Chinese clinical trial registries). Thiotepa is a well-established alkylating agent used primarily in conditioning regimens for hematopoietic stem cell transplantation (HSCT). The provided context refers to a Phase 4 clinical trial (ChiCTR2600130758) conducted by The First Affiliated Hospital of Zhengzhou University, evaluating a **TBMF** conditioning regimen (typically comprising Thiotepa, Busulfan, Melphalan, and Fludarabine) for patients with relapsed/refractory or minimal residual disease (MRD)-positive acute myeloid leukemia (AML). Thiotepa functions by forming ethylenimine groups that cross-link DNA strands, thereby inhibiting DNA replication and cell division. The suffix -mab in cetiplimab incorrectly suggests a monoclonal antibody modality, which does not correspond to the chemical entity cetipae or the chemotherapy-based TBMF regimen described.

Other names

cetiplimabcetipaethiotepasaitipai